http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#Head http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#provenance http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#pubinfo http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion http://purl.obolibrary.org/obo/DOID_13146 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_13146 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00520 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association http://www.w3.org/2000/01/rdf-schema#label caspofungin acetate is an echinocandin antifungal indicated in adults and pediatric patients 3 months of age and older for empirical therapy for presumed fungal infections in febrile neutropenic patients 1 treatment of candidemia and the following candida 1 treatment of esophageal candidiasis 1 treatment of invasive aspergillosis in patients who are refractory to or intolerant of other therapies 1 caspofungin acetate for injection is indicated as empirical therapy for presumed fungal infections in febrile neutropenic adult and pediatric patients 3 months of age and older see clinical studies 14 1 14 5 caspofungin acetate for injection is indicated for the treatment of candidemia and the following candida infections intra abdominal abscesses peritonitis and pleural space infections in adult and pediatric patients 3 months of age and older see clinical studies 14 2 14 5 limitations of use candida caspofungin acetate for injection is indicated for the treatment of esophageal candidiasis in adult and pediatric patients 3 months of age and older see clinical studies 14 3 14 5 limitations of use see clinical studies 14 3 caspofungin acetate for injection is indicated for the treatment of invasive aspergillosis in adult and pediatric patients 3 months of age and older who are refractory to or intolerant of other therapies see clinical studies 14 4 14 5 limitations of use http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00520 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#provenance http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#pubinfo http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig http://purl.org/nanopub/x/hasSignature WJSKHDkHvF5pI97AfODVSSuuoGGHmcj2X/YcTrOd6TLd7UWKy9WpFxSyV64oEh/6mYGoGyos22dI16+E5ATJIqxAUlNfc+EtY6HCtf3Nr3/zwojqrF/mrMtaCKRVfQqLemynRYmGvwc93KMezAM/ezGRE5aAV8wLUImYA6MjGVE= http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://purl.org/dc/terms/created 2021-06-13T16:37:05.692+02:00 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAGYO-YzYa850-O5g_44ngm3OCOEdOJhNwIabBysG77H8 https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs